Stay informed and keep abreast with our media news.
HKET – 疫情加速了科技融入医药学科研范畴，生物科技行业开始获得市场关注。专注于核糖核酸（RNA）科技的新加坡高生物科技企业「觅瑞」（MiRXES），自2014年起致力于研发疾病早诊技术与将其商业化。现时业务遍布香港、中国、日本、美国等45个国家及地区，故吸纳人才成为其首要挑战。 该企藉创造一个较人性化及较灵活的工作环境等3招，以招徕人才。
InvestHK – MiRXES is a biotechnology company founded in 2014. It translates research discoveries to deliver early detection of multiple cancers using proprietary RNA-powered blood tests. In 2021, MiRXES established its Hong Kong office to support its business expansion in the city and in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) to accelerate the global development of a truly preventive healthcare system.
Portfolio – If Dr Zhou Lihan had his way, preventive healthcare, more particularly, the early diagnosis of cancer using fuss-free cancer tests, even when no symptoms are displayed, would be the driving force of the medical field in the future. It’s a noble cause and one that’s deeply personal.
Business Times – Long before Covid-19 struck, local biotech company Mirxes had, for seven years, been developing polymerase chain reaction (PCR) tests to detect cancer. This allowed Mirxes to pivot quickly to making Covid-19 test kits when the need arose. The first locally made Covid-19 test kit was developed within just three weeks.
Singapore Business Review – MiRXES won two trophies at the 2021 SBR Management Excellence Awards. The company was awarded the Team of the Year trophy while MiRXES Co-founder and CEO, Dr. Zhou Lihan was named Executive of the Year for Biotechnology.
Business Times – Biotechnology startup MiRXES’ co-founders Zhou Lihan, Zou Ruiyang and chief investment officer Isaac Ho have been named the EY Entrepreneur of the Year 2021 Singapore (EOY).
The Edge – Traditionally, most cancers are detected through imaging techniques such as a CT scan or MRI. However, this process is not effective at detecting those with asymptomatic cancer, explains Zhou. The problem with this is that the cancer will only be detected at a later stage, meaning that the intervention would be late and treatment pre- scribed different.
Business Times – MiRXES believed the future of healthcare would shift from treating the sick to preventive healthcare, and successfully brought its technology from laboratory to clinic. They took a leap of faith, trusted their instincts, looked at the big picture and more importantly, pressed on when the going got tough.
The Peak – Imagine this: you walk into a clinic for an early detection test that identifies biomarkers in your blood to detect potentially life-threatening diseases in their early stages when they are still asymptomatic. In the stylish waiting room, you nibble on a croissant and sip a latte. You almost feel like you are at a spa, not a medical clinic.
Channel NewsAsia –
A global innovation hotspot, Singapore is grooming creative talents from diverse fields. What exciting projects can we find in this future-ready city?
Produced in partnership with Ministry of Trade and Industry (MTI), Singapore
Bertia Harian– Satu skim biasiswa bernilai $140,000, yang dilancarkan Yayasan Mendaki dan syarikat bioteknologi MiRXES akan membolehkan pelajar sarjana muda dan possiswazah Melayu/Islam melanjutkan pelajaran mereka dalam sains hayat dan bioperubatan.
Berita Mediacorp – Penuntut Melayu/Islam dalam bidang Sains Hayat dan Bioperubatan kini mendapat satu lagi sokongan serta peluang pekerjaan dalam bidang itu, hasil biasiswa yang dilancarkan hari ini (23 Okt) oleh Yayasan MENDAKI dan syarikat bioteknologi MirXES. Bernilai S$140,000 kesemuanya, Biasiswa MENDAKI-MiRXES itu juga menawarkan peluang latihan industri (internship) dan bekerja dengan syarikat itu setelah tamat pengajian.
Vulcan Post – The onset of Covid-19 has rocked healthcare systems worldwide and left governments all over the world scrambling to combat the pandemic. It’s been tough, and there is still a long road ahead of us. If there is any positive outcome out of this, it is how it served as a catalyst for innovation, especially for the medical technology (MedTech) sector.
360DX – Two years after the launch of its first microRNA-based cancer screening assay, MiRxes is looking to expand and diversify its product portfolio with additional PCR tests for cancers and the early detection of cardiovascular, metabolic, and infectious diseases
Lianhe Zaobao – 今年有来自五家公司的七名企业家入选竞逐安永新加坡年度企业家奖。
The Edge – EY has named seven entrepreneurs from five organizations as recipients of the 20th EY Entrepreneur Of The Year (EOY) 2021 Singapore awards, in recognition of their proven ability and track record befitting this year’s theme “The Unstoppables”.
CEO Magazine –The creation of MiRXES was all about teamwork; working together to address cancer screening, one of health care’s most challenging, unmet needs. “The setting up of MiRXES was the collective vision of the team,” reveals the company’s Co-Founder and CEO Lihan Zhou. “Our goal is quite simple: we want to improve and save lives.
Business Times – PROFESSIONAL services organisation EY on Monday (Oct 11) named 7 entrepreneurs as category winners of its 20th EY Entrepreneur Of The Year 2021 Singapore awards.
CNBC – Start-ups disrupting the financial services, health care and commerce industries are among the best to work for in Singapore, according to a new study from LinkedIn.
The Edge – MiRXES, a Singapore biotechnology startup, has appointed Dr David Capes as its senior vice president and new global head of innovation on Sept 20.
Business Times – MiRXES has raised US$77 million in a Series C round, pushing to commercialise its early cancer detection test kits globally. This latest round values the biotech at over US$500 million and could pave the way for a public listing.
For media enquiries, please email: email@example.com